Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Slow Aging Pathway Associated with Development of Brain Cancer

XTALKS VITALS NEWS

Glioblastoma

The study – published in the journal, Proceedings of the National Academy of Sciences – found that the NAD+ pathway is upregulated in the most common and aggressive form of brain cancer in adults, glioblastoma.

Share this!

December 9, 2016 | by Sarah Hand, M.Sc.

A metabolic pathway associated with slower aging – known as the NAD+ pathway – has now been implicated in the development of brain cancer. The study – published in the journal, Proceedings of the National Academy of Sciences – found that the NAD+ pathway is upregulated in the most common and aggressive form of brain cancer in adults, glioblastoma.

More than 70 percent of patients with glioblastoma don’t live more than two years after diagnosis. This new study found that patients whose glioblastoma displayed high expression of the NAMPT gene, which is involved in the NAD+ pathway, faced shorter life expectancies.

Further, when NAMPT-overexpressing tumors were implanted into mice, they grew rapidly. When the gene was inhibited, the tumors shrank suggesting that the NAD+ pathway could be a good target for glioblastoma therapies.

However, inhibiting this gene could have negative effects on patient aging. The gene products of the NAMPT gene is nicotinamide mononucleotide (NMN), a compound that has shown efficacy in slowing signs of aging in mice.

“There's a lot of buzz about taking NAD+ precursors for their anti-aging effects, which is based on a lot of great science,” said Dr. Albert H. Kim, an assistant professor of neurological surgery and the senior author on the paper. “We didn't directly demonstrate that taking NAD+ precursors makes tumors grow faster, but one implication of our work is that if you want to take anti-aging NAD+ precursors, you might want to keep in mind that we don't yet understand all the risks.”



Kim and his colleagues found that NAMPT was important in allowing human glioblastoma cells to survive and divide. When NAMPT was inhibited, the glioblastoma cells became sensitive to radiation therapy, which is one of the most common cancer treatments for a variety of forms of the disease.

“If you target the NAD+ pathway, you can disrupt the ability of the cancer stem cells to self-renew, and you can also make them more sensitive to radiation treatment,” said Kim. “In a patient, that could mean that if you suppress the pathway, the same dose of radiation may be more effective at destroying the tumor.”

As the NAD+ pathway is very complex, and not fully understood, Kim cautions against tinkering with the machinery before we can accurately predict the results. A human clinical trial assessing the safety of NMN is currently being conducted in Japan, however the molecule is already being marketed there as an anti-aging supplement.


Keywords: Aging, GlioblastomaCancer


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.